Silexion Therapeutics (NASDAQ:SLXN) Shares Down 7.2% – Time to Sell?

Silexion Therapeutics Corp (NASDAQ:SLXN) shares traded down 7.2% during trading on Friday . The company traded as low as $2.48 and last traded at $2.58. 7,291 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 47,613 shares. The stock had previously closed at $2.78.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Silexion Therapeutics currently has an average rating of “Hold”.

Silexion Therapeutics Trading Down 7.2%

The stock has a 50 day moving average of $3.56 and a 200-day moving average of $11.24. The company has a market capitalization of $1.08 million, a P/E ratio of -0.03 and a beta of -0.26.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($12.90) by $12.05. As a group, sell-side analysts expect that Silexion Therapeutics Corp will post -45.5 EPS for the current fiscal year.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.